Axsome Therapeutics Inc. (AXSM)’s Financial Results Comparing With Surface Oncology Inc. (NASDAQ:SURF)

Both Axsome Therapeutics Inc. (NASDAQ:AXSM) and Surface Oncology Inc. (NASDAQ:SURF) are each other’s competitor in the Biotechnology industry. Thus the compare of their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axsome Therapeutics Inc. N/A 0.00 28.80M -1.13 0.00
Surface Oncology Inc. 52.13M 2.92 17.66M -0.54 0.00

Table 1 highlights Axsome Therapeutics Inc. and Surface Oncology Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Axsome Therapeutics Inc. 0.00% -310.9% -113.7%
Surface Oncology Inc. -33.88% 63.7% 15.3%


Axsome Therapeutics Inc. has a Current Ratio of 1.5 and a Quick Ratio of 1.5. Competitively, Surface Oncology Inc.’s Current Ratio is 6.4 and has 6.4 Quick Ratio. Surface Oncology Inc.’s better ability to pay short and long-term obligations than Axsome Therapeutics Inc.

Insider and Institutional Ownership

Axsome Therapeutics Inc. and Surface Oncology Inc. has shares held by institutional investors as follows: 11.9% and 63.4%. Insiders held roughly 0.1% of Axsome Therapeutics Inc.’s shares. Insiders Comparatively, held 14.85% of Surface Oncology Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Axsome Therapeutics Inc. 3.99% -13.52% 7.62% 1.19% -27.1% -39.46%
Surface Oncology Inc. 3.47% -3.46% -14.61% -41.42% 0% -37.28%

For the past year Axsome Therapeutics Inc. was more bearish than Surface Oncology Inc.


Surface Oncology Inc. beats Axsome Therapeutics Inc. on 8 of the 9 factors.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.